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The Chronic Kidney Disease in Children study is a cohort of
about 600 children with chronic kidney disease (CKD) in the
United States and Canada. The independent variable for our
observations was a measurement of glomerular filtration rate
(GFR) by iohexol disappearance (iGFR) at the first two visits 1
year apart and during alternate years thereafter. In a previous
report, we had developed GFR estimating equations utilizing
serum creatinine, blood urea nitrogen, height, gender, and
cystatin C measured by an immunoturbidimetric method;
however, the correlation coefficient of cystatin C and GFR
(0.69) was less robust than expected. Therefore, 495
samples were re-assayed using immunonephelometry. The
reciprocal of immunonephelometric cystatin C was as well
correlated with iGFR as was height/serum creatinine (both
0.88). We developed a new GFR estimating equation using
a random 2/3 of 965 person-visits and applied it to the
remaining 1/3 as a validation data set. In the validation data
set, the correlation of the estimated GFR with iGFR was 0.92
with high precision and no bias; 91 and 45% of eGFR values
were within 30 and 10% of iGFR, respectively. This equation
works well in children with CKD in a range of GFR from 15
to 75ml/min per 1.73m2. Further studies are needed to
establish the applicability to children of normal stature and
muscle mass, and higher GFR.
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Cystatin C is a small-molecular-weight protein that is
produced ubiquitously at a regular rate, and its reciprocal
has been shown to be highly correlated with glomerular
filtration rate (GFR).1–4 This relationship is independent of
inflammatory conditions, muscle mass, gender, body com-
position, and age (after 12 months).5,6 Cystatin C levels are
slightly below 1mg/l in the blood of healthy individuals.7 The
protein is catabolized and almost completely reabsorbed by
renal proximal tubular cells, so that little is normally excreted
in the urine.8 Inter-individual variation in cystatin C account
for 25% of its biological variability compared to 93% for
creatinine.9 Thus, the upper limit of the population reference
interval for cystatin C is seldom more than 3–4 s.d. from the
mean value of any healthy individual (compared to 13 s.d. for
creatinine).
Cystatin C is commonly quantified using either an
automated particle-enhanced turbidimetric immunoassay
or particle-enhanced nephelometric immunoassay to mea-
sure the formation of antigen-antibody complexes. Turbidi-
metry refers to the measurement of transmitted light at the
same wavelength and direction as the incident beam,
whereas nephelometry refers to detection of light scattered
and leaving the solution at some angle other than that of
the incident beam.10 The nephelometric method is more
sensitive10 and performs optimally in dilute solution,
making it preferable for small sample volumes encountered
in the pediatric population. It should also be noted that
there are discrepancies in the determination of cystatin C in
the same blood samples between the Dako turbidimetric
particle-enhanced turbidimetric immunoassay and the Sie-
mens Healthcare Diagnostics (formerly Dade Behring)
particle-enhanced nephelometric immunoassay method,11,12
suggesting different reactivity to the antibodies against the
cystatin C molecule, different standards, or different
substrates.11 Indeed, in a previous meta-analysis of
the correlation between cystatin C and measured GFR,1 the
mean correlation coefficient was significantly greater for the
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immunonephelometric assay (r¼ 0.832) compared with
other cystatin C assays (r¼ 0.784).
Some studies in children have shown that the concentration
of serum cystatin C is better correlated with GFR than is the
concentration of serum creatinine (Scr).5,13 Moreover, subtle
decrements in GFR may be more readily detected by changes
in serum cystatin C than by Scr,13 due in part to the shorter
half-life of cystatin C. Because nephelometric cystatin C levels
in serum are well correlated with GFR in adults14,15 and in
children,2,3,16,17 we sought to develop a new GFR estimating
equation using cystatin C that was measured by an immuno-
nephelometric assay and enzymatic creatinine for children
with chronic kidney disease (CKD).
The Chronic Kidney Disease in Children (CKiD) study is a
National Institutes of Health-funded cohort study of B600
children with mild-to-moderate CKD in the United States
and Canada. Its purposes are to determine risk factors for
further renal progression, cardiovascular morbidity, growth
failure, and neurocognitive impairment. Since the primary
measure of disease progression is the decline in GFR, the
study determines GFR by iohexol plasma disappearance
(iohexol GFR, iGFR). However, to improve recruitment and
retention and reduce participants’ burden and costs, iGFR is
measured at the first two study visits and every other annual
study visit thereafter. Accordingly, GFR would be estimated at
the other visits using equations developed from endogenous
biomarkers and measurements of body habitus.
We believed it would be important to utilize cystatin C, in
addition to height(ht)/Scr, in developing these GFR estimat-
ing equations. Such GFR estimating equations have been
previously published using CKiD data incorporating cystatin
C analyzed by Dako immunoturbidimetry.18 We found that
the ht/Scr term provided substantially more weight to the
estimating equation than did the cystatin C term, indicating
that the latter analyte was less well correlated with iGFR than
was ht/Scr.18 We questioned whether the methodology of
cystatin C analysis was limiting our ability to accurately
predict GFR. Whereas creatinine is now being referenced to
isotope dilution mass spectrometry,19 the process is just
beginning for cystatin C.20
RESULTS
Paired comparisons of 495 turbidimetric and nephelometric
assays of cystatin C
The median turbidimetric (Dako) cystatin C was 1.88
(interquartile range¼ 1.54 to 2.37), compared with the
nephelometric (Siemens Healthcare) median of 1.78 (inter-
quartile range¼ 1.41 to 2.33). Figure 1 shows the box-
percentile plots of the two determinations with solid lines
connecting the 495 paired samples. The Figure and the
corresponding Bland-Altman analysis show that the turbidi-
metric method had a positive bias of 6.9% (Po0.001) and a
5.2% (P¼ 0.103) smaller standard deviation compared with
the nephelometric method, and the correlation between the
two methods measuring the same analyte was only modest
(r¼ 0.77). More importantly, the reciprocal of cystatin C
measured by the nephelometric method showed substantially
stronger correlations with iGFR (0.87 for nephelometric vs.
0.74 for turbidimetric), ht/Scr (0.82 vs. 0.70), and 1/blood
urea nitrogen (BUN; 0.66 vs. 0.54).
Comparison of univariate cystatin C and ht/Scr equations to
estimate GFR
In contrast to the poorer diagnostic performance of turbidi-
metric cystatin C relative to ht/Scr,18 using a total of 965
person-visits with cystatin C measured by the nephelometric
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Figure 1 |Box-percentile plots of cystatin C measured using the Dako turbidimetric method vs. the Siemens Healthcare
nephelometric method in N¼ 495 person-visits.
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method, we found a univariate cystatin C-based eGFR
equation of 40.6 (1.8/cystatin C)0.93 with an R2 of 76.1%
(Figure 2), which was very close to the R2 of 77.1% provided
by the univariate ht/Scr-based eGFR of 42.3 (ht/Scr)0.79
(Figure 3). Furthermore, Figure 4 shows that both methods
provided median values that were within 0.7ml/min per
1.73m2 of the median of the iGFR; and as is the case of all
estimating equations, the dispersions from each equation were
equally smaller relative to the dispersion in iGFR. However,
the cystatin C-based equation overestimated several of the low
iGFRs. Specifically, Figure 2 shows that for values of 1.8/
cystatin Co1/2 (i.e., cystatin C 43.6mg/l), several iGFR
values were substantially overestimated. On the other hand,
ht/Scr performed well throughout the range of measurement
(Figure 3).
There were 176 studies in which eGFR using ht/Scr
differed from eGFR using cystatin C by more than 30%, but
these estimates were comparably correlated with iGFR. There
was no systematic reason that explained the deviation from
iGFR for either estimating equation.
Estimation of GFR from the training set
In order to develop a multivariate equation to estimate GFR,
we selected a 2/3 random sample training set (n¼ 643) from
the 965 person-visits; the complement 1/3 (n¼ 322) was used
for the purposes of validating our proposed equations. The
descriptive statistics of the two groups showed as expected,
great comparability (Table 1). In the training set of 643
person-visits, univariate eGFR could be determined with
approximately similar confidence and accuracy by using
either cystatin C or ht/Scr (R2¼ 77.1 vs. 78.5%, Table 2); the
use of BUN alone was clearly inferior (R2¼ 50.2%). Bivariate
analysis showed that the combination of cystatin C and ht/
Scr (Models I and II, Table 2, Bivariate models) strongly
improved the GFR estimating equation, increasing R2 to
84.3%, decreasing root mean squared error to 0.157ml/min
per 1.73m2, and further increasing accuracy such that 90.1
and 46.5% of eGFRs were within 30 and 10%, respectively, of
measured iGFR; other bivariate combinations using BUN
were less accurate and less precise. Whereas there was further
improvement using a multivariate equation with cystatin C,
ht/Scr, and BUN, the most accurate and effective GFR
estimating equation incorporated a gender and a separate
height term (Final model, Table 2). This equation, eGFR (ml/
min per 1.73m2)¼ 39.8(ht(m)/Scr(mg/dl))0.456(1.8/cystatin
C (mg/l))0.418 (30/BUN(mg/dl))0.079 (1.076male) (ht(m)/
1.4)0.179, utilized a format that was originally published
using turbidimetric cystatin C values,18 improved R2 to
86.3%, reduced the root mean squared error to 0.147ml/min
per 1.73m2, and improved accuracy such that 91.3 and 48.8%
of the estimates were within 30 and 10% of measured iGFR,
respectively. The nearly identical exponents for 1.8/cystatin C
and ht/Scr suggest that both variables contribute equally to
the estimation of GFR.
Validation of estimated GFR
We applied the estimated GFR equations described above to
the remaining 1/3 validation set (322 person-visits; Table 3).
Univariate ht/Scr- and cystatin C-based eGFR were nearly
equivalent: correlations between iGFR and equation specific
eGFRs were 0.84 and 0.85, respectively, but not as good as the
bivariate equation using both of these parameters (r¼ 0.90).
The multivariate equation using ht/Scr, cystatin C, and BUN
was slightly better, but the final equation, which added terms
for gender and height, was the best. Specifically, the correlation
was 0.92; 91.0 and 45.0% of eGFR values were within 30 and
10% of iGFR, respectively; and most importantly there was
no bias.
The univariate cystatin C GFR estimating equation was
compared with others developed in children (Table 4). The
relationship of eGFR with cystatin C conforms to a
hyperbolic curve for each of the formulas presented in
Table 4. However, the Filler and Lepage equation4 consis-
tently yielded higher GFR estimates for the same cystatin C
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Figure 2 |Univariate analysis of log(iGFR) vs. log(1.8/(cystatin
C (Siemens Healthcare)) in N¼ 965 person-visits. eGFR,
estimated glomerular filtration rate; iGFR, iohexol glomerular
filtration rate.
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Figure 3 |Univariate analysis of log(iGFR) vs. log(ht/Scr) in
N¼ 965 person-visits. eGFR, estimated glomerular filtration rate;
ht, height; iGFR, iohexol glomerular filtration rate; Scr, serum
creatinine.
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value indicating a significant positive bias. The Zappitelli
et al.21 and Hoek et al.22 equations slightly overestimated
GFR at cystatin C values below 1.3, and slightly under-
estimated GFR at cystatin C values above 1.3. Overall,
Zappitelli’s and Hoek’s equations showed similar lack of bias,
precision, and accuracy when compared with the CKiD
univariate (i.e., cystatin C) equation, but the percentage of
eGFR within 30% of iGFR was higher for the CKiD equation.
We then assessed whether race, hypertension, weight,
serum albumin, or steroid use were different in the person-
visits in which the difference between eGFR and iGFR was
410ml/min per 1.73m2 (‘outliers’) compared with person-
visits when the difference between eGFR and iGFR was
p10ml/min per 1.73m2 using four different estimates of
GFR (Scr-based, cystatin C-based, Scr-, and cystatin C-based,
final model). We found that the ‘outliers’ were consistently
associated with heavier weight. More specifically, there were
not many measurements contributed by participants with
low weight in whom eGFR underestimated iGFR. No other
factor significantly predicted a poor estimate of GFR.
DISCUSSION
Value of cystatin C in estimating GFR
The CKiD study is an observational study designed to
monitor the effect of CKD progression on cardiovascular
morbidity, growth failure, and neurocognitive impairment.
The independent variable in this study is the determination
of GFR. In order to reduce costs and improve recruitment,
the 5-h iohexol plasma disappearance GFR determination is
only performed in alternate years after the first two annual
study visits. Accordingly, we have developed equations to
estimate GFR during the years when iohexol GFR is not
measured. Our bedside formula for estimating GFR,
(41.3ht(m)/Scr), has become a useful tool for recruitment
and local use and for rapidly estimating GFR when cystatin C
values are not available.18 In addition, while underestimating
iGFR by an average of 2.23ml/min per 1.73m2, our
previously published multivariate GFR estimating equation,18
which utilized the Dako turbidimetric cystatin C, was more
accurate than reported equations based on ht/Scr alone and
performed better than other published equations within the
range of GFR of the subjects in the CKiD study.18 On the
other hand, iGFR was less well correlated with turbidimetric
cystatin C than with ht/Scr;18 this contradicted the work done
by Filler and Lepage,4 which indicated the better diagnostic
performance of nephelometric determination of cystatin C
over ht/Scr in estimating GFR in children. Given these
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Figure 4 |Box-percentile plots illustrating ht/Scr-based and nephelometric cystatin C-based eGFR vs. iGFR in N¼ 965 person-visits.
eGFR, estimated glomerular filtration rate; ht, height; iGFR, iohexol glomerular filtration rate; Scr, serum creatinine.
Table 1 | Descriptive statisticsa of the training and validation
samples from the CKiD cohort study
Training 2/3 random
sample (n=643)
Validation 1/3 random
sample (n=322)
Height, m 1.4 (1.2, 1.6) 1.4 (1.2, 1.6)
Serum creatinine, mg/dl 1.3 (1.0, 1.9) 1.4 (1.0, 2.0)
Height (m)/serum
creatinine (mg/dl)
1.0 (0.8, 1.4) 1.0 (0.7, 1.3)
Nephelometric
cystatin C, mg/l
1.7 (1.3, 2.3) 1.7 (1.3, 2.3)
Blood urea
nitrogen, mg/dl
28.0 (21.0, 39.0) 28.0 (22.0, 41.0)
Male 61% (389) 64% (207)
Iohexol-based GFR,
ml/min per 1.73m2
43.3 (32.6, 55.6) 42.4 (31.0, 55.6)
Abbreviations: CKiD, The Chronic Kidney Disease in Children study; GFR, glomerular
filtration rate.
aMedian (interquartile range) reported for continuous variables, percentage (n)
reported for male gender.
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conflicting results, we felt that the method of measuring
cystatin C should be evaluated and performance monitored.
Comparison of turbidimetric and nephelometric cystatin C
measures in estimating GFR
Figure 1 showed that paired comparisons of nephelometric
and turbidimetric cystatin C values were not as well
correlated (r¼ 0.77) as might be expected for measurement
of the same analyte; similar findings have been previously
published11,23 and have been suggested in a meta-analysis.1
Furthermore, GFR and other endogenous biomarkers (Scr
and BUN) were better correlated with nephelometric cystatin
C than with the turbidimetric cystatin C measurement.
Without comparisons to isotope dilution mass spectrometry
standards, it is not possible to comment specifically on which
method yields truer values of cystatin C. However, it is
evident that the nephelometric method better predicts iGFR.
Clearly, standardization of cystatin C calibrators, as recently
done for creatinine,24 may help to reconcile some differences
in the determination of cystatin C.20,25 Such calibrators are
not yet available for our immunonephelometric assay.
When one estimates GFR using cystatin C alone, the
best equation was eGFR¼ 40.9(1.8/cystatin C)0.931 or
70.69(cystatin C0.931), and this provides accuracy and corre-
lation that is comparable to estimates determined from ht/Scr
(Tables 2 and 3). Compared with the univariate cystatin C
GFR estimating equation of Filler and Lepage,4 which was
generated from children with mild CKD and a mean single
slope 99mTc-DTPA single injection GFR measurement of
103ml/min per 1.73m2, the CKiD equation was more
accurate and less biased (Table 4). In addition, there were
no major differences in bias, precision, or accuracy between
the CKiD equation and the univariate cystatin C estimating
equations of Zappitelli et al.21 and Hoek et al.22 Interestingly,
the Zappitelli equation was developed using children with
mild-to–moderate CKD as indicated by a mean iothalamate
infusion clearance of 74ml/min per 1.73m2.21 The Hoek
equation was generated from adults with CKD
and a median iothalamate renal clearance of 81ml/min
per 1.73m2.22 Whereas bivariate estimating equations utiliz-
ing both cystatin C and ht/Scr proved superior to both
univariate equations, as previously shown by us18 as well as
by Zappitelli et al.21 and Bouvet et al.,26 improved accuracy,
correlation, and precision were obtained by including ht/Scr,
cystatin C, and BUN plus an extra component for height and
gender (Tables 2 and 3). As seen in Tables 2 and 3, this
multivariate equation performed better than any of the
univariate or bivariate equations.
Consideration of univariate GFR estimating equations
Although the combined prediction equations provide the
best accuracy and performance, there are situations in which
one of the biomarkers is unusually affected, and probably
diminishes its effectiveness. For example, severe reductions of
muscle mass or increased muscle mass with heavy weight
training will adversely affect Scr without necessarily affecting
GFR. Similarly, high doses of glucocorticoids, thyroid disease,
or significant inflammation may adversely affect cystatin C.27
However, in our sample, C-reactive protein and white blood
cell count were not significantly correlated with serum
cystatin C level (data not shown). Studies in adults suggest
that estimates of GFR by cystatin C are not superior to those
based on creatinine,25,28,29 even if cystatin C is a better
predictor of cardiovascular disease than is creatinine. Indeed,
factors other than GFR affect serum cystatin C levels in
adults,30,31 but this did not appear to be the case in our CKiD
population.
Another issue affecting GFR estimation is the validity of
the GFR measurement. The CKiD study utilizes the plasma
disappearance of iohexol. Although renal inulin clearance is
still recognized as the gold standard for measuring GFR,
practical matters limit the application of such methodology
in children. First, inulin is not readily available and is difficult
to measure. Second, as 80% of the recruited CKiD subjects
Table 2 | Precision, goodness of fit, and agreement of eGFR derived from coefficients of indicated regression model; N=643
(i.e., 2/3 of 965) training set children-visits of the CKiD study
eGFR ¼a ðheight=ScrÞb ð1:8=Cystatin CÞc ð30=BUNÞd ðemaleÞ ðheight=1:4Þf
Model a b c d e f
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
MSE
p
R2
% of eGFR
within 30%
of iGFR
% of eGFR
within 10%
of iGFR
Univariate
I: ht/SCr 42.3±0.3 0.780±0.016 0.184 78.5% 84.3 40.4
II: Cystatin C 40.9±0.3 0.931±0.020 0.190 77.1% 84.9 42.3
III: BUN 41.0±0.5 0.613±0.024 0.280 50.2% 67.8 26.1
Bivariate
I and II 41.6±0.3 0.443±0.026 0.479±0.031 0.157 84.3% 90.1 46.5
I and III 41.9±0.3 0.662±0.021 0.171±0.021 0.175 80.6% 86.5 42.8
II and III 40.8±0.3 0.796±0.027 0.157±0.022 0.183 78.7% 84.9 42.8
Multivariate
I and II and III 41.5±0.3 0.417±0.026 0.431±0.032 0.088±0.019 0.155 84.8% 89.4 47.1
Final 39.8±0.4 0.456±0.026 0.418±0.031 0.079±0.018 1.076±0.013 0.179±0.032 0.147 86.3% 91.3 48.8
Abbreviations: BUN, blood urea nitrogen (mg/dl); CKiD, Chronic Kidney Disease in Children study; cystatin C (mg/l); eGFR, estimated glomerular filtration rate (ml/min per
1.73m2); height (m); iohexol GFR (ml/min per 1.73m2); MSE, mean square error; Scr, serum creatinine (mg/dl).
Entries for a–f are regression coefficient±s.e.
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have non-glomerular disease,32 a significant fraction is likely
to have vesicoureteral reflux or dysfunctional bladder
emptying, making urine collections for inulin assay extremely
inaccurate. Parents are also unlikely to allow biennial urine
catheterization of their children to measure GFR. Thus, it
would seem preferable to use plasma disappearance clear-
ances to avoid this situation. Radioactive studies on a
biennial basis also cannot be easily recommended due to the
accumulated burden, necessitating the use of non-radioactive
agents. As iothalamate is secreted by the kidney,33 the
decision was made to use iohexol as the GFR agent.34 Most
studies indicate close agreement between GFR (measured by
inulin clearance) and clearance of iohexol, measured as
standard renal clearance or plasma disappearance,35–39 and
some authors believe iohexol has become the new gold
standard.36
Optimization of the performance of the iGFR pilot study
showed that blood iohexol sampling could be reduced from
nine to four time points to characterize a two-compartment
system34 and subsequently to three points40 and two points41
as the monoexponential (renal) curve could be well
correlated with two-compartment GFR via coefficients
derived from a specific approach as developed originally by
Brochner-Mortensen.42
Use of univariate ht/Scr- and cystatin C-based GFR estimating
equations
On the basis of the pioneering work by Grubb,43 we can
recommend an alternate approach to estimating GFR in children.
GFR in ml/min per 1.73m2 is estimated from univariate formulas
utilizing ht(m)/Scr and cystatin C for ht/Scr: eGFR¼ 42.3(ht/
Scr)0.78 for the bedside formula: eGFR¼ 41.3(ht/Scr), and for
cystatin C: eGFR¼ 70.69(cystatin C)–0.931). These two eGFRs are
compared and if they agree, within a certain specified limit
(perhaps 10ml/min per 1.73m2 in the CKiD population, or
within 15–20% in a general pediatric population), they can be
averaged to provide an accurate non-invasive eGFR for the
patient or subject. If there is disagreement between the two
estimates, and a reason can be found, such as decreased muscle
mass, then the eGFR determined from cystatin C would be used;
similarly, with the use of high doses of corticosteroids, the eGFR
determined from ht/Scr could be utilized. When there is no
obvious reason for a discrepancy greater than 10ml/min (or
15–20%) between eGFRs from ht/Scr and cystatin C, it may be
necessary to directly measure GFR. Interestingly, in our CKiD
population, the only variable resulting in ‘outliers’ from the
univariate (and multivariate) GFR estimating equations was
heavier weight. There was no association with race, hypertension,
serum albumin, or use of steroids.
Table 3 | Application of CKiD prediction equations to 1/3 validation set of 322 person-visits of the CKiD study with iGFR
44.4±17.2ml/min per 1.73m2
Model eGFR Biasa 95% LOAb Correlation
% of eGFR within
30% of iGFR
% of eGFR within
10% of iGFR
Univariate
I: ht/SCr 43.4±13.5 1.0 19.2, 17.1 0.84 80.4 36.0
II: Cystatin C 44.7±15.2 0.3 17.5, 18.1 0.85 82.6 37.6
III: BUN 43.0±11.5 1.4 25.3, 22.5 0.71 65.5 27.3
Bivariate
I and II 44.1±14.6 0.3 15.4, 14.7 0.90 88.8 38.2
I and III 43.4±13.7 1.0 17.5, 15.5 0.87 83.9 35.1
II and III 44.6±15.3 0.1 16.7, 17.0 0.87 82.3 35.4
Multivariate: I, II, and III 44.1±14.7 0.4 14.9, 14.2 0.90 89.1 41.9
Final 44.2±14.9 0.2 13.4, 13.0 0.92 91.0 45.0
Abbreviations: BUN, blood urea nitrogen (mg/dl); CKiD, Chronic Kidney Disease in Children study; eGFR, estimated glomerular filtration rate (ml/min per 1.73m2); ht, height;
iGFR, iohexol GFR; LOA, limits of agreement; Scr, serum creatinine.
aBias=average of 322 (eGFR–iGFR) values, in ml/min per 1.73m2.
b95% LOA=bias ±1.96 s.d. of (eGFR–iGFR).
Table 4 | Application of univariate cystatin C prediction equations to 1/3 validation set of 322 person-visits of the CKiD study
with iGFR 44.4±17.2ml/min per 1.73m2
Equation eGFR Biasa 95% LOAb Correlation
% of eGFR within
30% of iGFR
% of eGFR within
10% of iGFR
CKiDc 44.7±15.2 0.3 17.5, 18.1 0.85 82.6 37.6
Zappitelli et al.21 d 43.5±18.7 1.0 20.5, 18.6 0.85 77.3 37.6
Filler and Lepage4 e 53.5±21.9 9.0 14.0, 32.0 0.85 64.3 21.7
Hoek et al.22 f 45.0±18.0 0.6 18.4, 19.6 0.85 78.6 37.9
Abbreviations: CKiD, Chronic Kidney Disease in Children study; eGFR, estimated glomerular filtration rate (ml/min per 1.73m2); iGFR, iohexol GFR; LOA, limits of agreement.
abias=average of 322 (eGFR–iGFR) values, in ml/min per 1.73m2.
b95% LOA=bias±1.96 s.d. of (eGFR–iGFR).
c70.69(cystatin C)0.931.
d75.94(cystatin C)1.170.
e91.62(cystatin C)1.123.
f4.32+80.35(cystatin C)1.
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Conclusions
Until a universal standardized cystatin C calibrator is
available,20 the CKiD study will use the present Siemens
Healthcare nephelometric method to measure cystatin C.
The equation: eGFR¼ 39.8 (ht(m)/Scr)0.456(1.8/cystatin
C)0.418(30/BUN)0.0791.076male(ht(m)/1.4)0.179 will be utilized
to estimate GFR at study visits when iohexol is not
administered. It shows high accuracy and precision and
minimal bias in the CKiD population. Confirmation of the
utility of this equation is desirable in other populations of
children with CKD. Further studies are needed to examine its
applicability in children with normal stature and muscle mass
and higher GFR. The use of univariate eGFR equations may
serve as a reasonable alternative to the multivariate equation
when there is a concern about one of the major variables (ht,
Scr, or cystatin C). In most children with CKD the bedside
equation (41.3ht(m)/Scr) allows rapid and reasonably
accurate estimation of GFR for clinical use. When measure-
ment and calibration is more broadly available, GFR
estimates using cystatin C may also have broad clinical utility.
MATERIALS AND METHODS
Study participants and basic assays
The CKiD study was approved by research review boards at all of the
participating sites in the United States and Canada. Eligible
individuals were 1 to 16 years of age with initial estimated GFR of
30 to 90ml/min per 1.73m2 (estimated by the original Schwartz
equation44,45) at each local site. Body surface area was computed
from height and weight using the formula of Haycock et al.46 Sera
were shipped to the CKiD Central Biochemistry Laboratory (CBL)
at the University of Rochester Medical Center (URMC) for
determination of BUN and enzymatic creatinine. Sera for cystatin
C were frozen and stored at 80 1C, and shipped quarterly to the
Children’s Mercy Hospital (CMH) in Kansas (S Hellerstein) prior to
June 2008. Subsequently, frozen sera for cystatin C were directly
shipped from the sites to the CBL on a quarterly basis.
Specific assays
At the baseline and all even-numbered study visits, GFR was
measured by iohexol plasma disappearance.18,34,40 Iohexol (Omni-
paque) was provided by GE Healthcare (R Vitti, Amersham
Division, Princeton, NJ). Iohexol concentrations were determined
by high-performance liquid chromatography in the URMC
Toxicology laboratory.34 The inter-assay coefficients of variation of
30 separate runs of quality control iohexol samples were 5.8% at a
level of 12.1mcg/ml and 3.0% at 117mcg/ml. The intra-assay
coefficients of variation obtained from spiked iohexol samples at
two levels, six injections per level, on 3 different days averaged
1.95% at 14.77mcg/ml and 1.23% at 99.25mcg/ml. The limit of
quantification was 2mcg/ml.
The training set contained a total of 643 iGFR measurements, 498
(77.5%) measured from four iohexol concentrations taken at 10, 30,
120, and 300min and 145 (22.6%) measured from three iohexol
concentrations taken at 120, 240, and 300min. The validation set
contained a total of 322 iGFR measurements, 257 (79.8%) measured
from four iohexol concentrations taken at 10, 30, 120, and 300min
and 65 (20.2%) measured from three iohexol concentrations taken at
120, 240, and 300min. The four-point iohexol GFR measurement was
previously shown34 to comprise the fewest number of blood samples
needed to characterize the two-compartment iohexol plasma disap-
pearance curve. We have shown in a more recent analysis41 that there
was very good agreement between the four-point iGFR measurement
and the two-point iGFR that characterized only the renal (slow)
plasma disappearance curve along with a formula relating the slow
GFR to the two-component (slow þ fast) GFR.
BUN and enzymatic creatinine were analyzed on an Advia 2400
(Siemens Diagnostics, Tarrytown, NY); the creatinine assay had
been validated using isotope dilution mass spectrometry reference
material.19
Cystatin C was originally measured at CMH by a turbidimetric
assay (Cystatin C Kit K0071; Dako SD, Copenhagen, Denmark).
Cystatin C was subsequently measured at the CBL using a Siemens
BN II nephelometer (prior to June 2008). Twenty microliters of 1%
sodium azide were added to the sera after assaying for cystatin C at
CMH. Volumes in the cryovials were estimated to the nearest 100ml
and corrected by the factor: volume/(volume20). Other samples
measured at the CBL, but not previously at CMH, were not diluted
in this way and did not require correction for the change in volume.
The Siemens nephelometric assay (order number OQNM13) was
performed with a six-point calibration generated from multiple
dilutions of a human cystatin C calibrator obtained from human
urine. The intensity of the signal is proportional to the cystatin C
sample concentration. Each run included 1–3 sera of known cystatin
C concentration to rule out drift of the assay. Each run of 10–60
samples was preceded and followed by measurement of quality
controls of low (1.06mg/l) and high (1.93mg/l) cystatin C
concentrations, and the runs were discarded if the quality controls
changed by more than 6% over the course of the assay. The assay
range is 0.195 to 7.330mg/l; the reference range for young healthy
persons ranges from 0.53 to 0.95mg/l.47,48 The inter-assay
coefficient of variation is 2.3–3.1%. There is no interference from
bilirubin, hemolysis, or lipids. Samples can be stored at least 6
months at 80 1C,47 and in preliminary studies, could be frozen and
thawed a few times without change in measured concentration.
There were 646 person-visits with dual measurements of cystatin
C by turbidimetry and nephelometry. There were 495 person-visits
with a concomitant successful iGFR and Scr. In total, there
were 1580 person-visits with cystatin C measured by nephelometry,
for which 965 had successful concurrent iGFR, Scr, and BUN
measured.
Statistical analyses
Bland-Altman analysis49 in the log scale was used to compare the
methods of cystatin C measurement. Univariate linear regression
analyses of cystatin C concentration were performed to determine
the correlation between the two cystatin C methods and iGFR, ht/
Scr, and BUN.
Standard regression techniques for Gaussian data were used to
determine the coefficients of GFR estimating equations after
logarithmic transformation of the iGFR, cystatin C, ht/Scr, and
BUN values. These continuous independent variables were centered
at the median values when entered into regression models. In this
way the model’s intercept represents the expected value of GFR for
the group of individuals with the constellation of predictors at the
centering values.
The general regression model was of the form:
logðiGFR½ml=min per 1:73m2Þ ¼ logðaÞ þ b logðXÞ þ cZþ e
where X is a constellation of continuous predictors (e.g., ht(m)/
Scr(mg/dl), 1.8/cystatin C(mg/l), 30/BUN)(mg/dl), ht(m)/1.4, Z is a
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categorical variable for sex, and e follows a normal distribution with
mean zero and variance s2 (where s2 corresponds to the expected
value of the mean square error). Therefore, a represents the expected
value of iGFR for the group whose values of the continuous
predictors are at the median values of the study population (e.g.,
ht(m)/Scr(mg/dl)¼ 1, cystatin C(mg/l)¼ 1.8, BUN(mg/dl)¼ 30)
and whose sex is female (reference category).
The estimated GFR (eGFR¼ a[X]b[exp(c)]Z) was obtained by
using the expected values of the regression coefficients (a, b, and c)
along with specific values of the independent variables (X and Z) for
each individual. To assess the performance of the estimating
equations we calculated: (i) the RMSE (square root of the mean
square error), which measures the unexplained variability of iGFR;
(ii) the R2, which measures the percentage of the variability in iGFR
explained by the predictors; (iii) the correlation between the
observed iGFR and eGFR; and (iv) the percentage of eGFR values
that were within 30 and 10% of the corresponding iGFR values
calculated on a 2/3 randomly chosen training sample (i.e., the one
used to develop the equations, n¼ 643) and on a validation sample
comprising the remaining 1/3 of the person-visits (n¼ 322).
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